Request an invite

Imdelltra: genotox, carcinogenicity and repro: done or skipped?

tarlatamab · DLL3 x CD3
Genotoxicity
Not conducted (ICH S6(R1))
“Therefore, no genotoxicity studies have been conducted or are planned, consistent with ICH Harmonised Tripartite Guideline S6”
✓ VerifiedFDA multi-discipline review, p. 73Source ↗
Carcinogenicity
Not conducted (ICH S9)
“No carcinogenicity studies have been conducted nor are any planned in accordance with ICH S9 (ICH, 2010).”
✓ VerifiedFDA multi-discipline review, p. 73Source ↗
Reproductive & developmental
Mouse EFD study with surrogate muS757 (GD6, GD13): no maternal or EFD toxicity up to 4500 µg/kg; placental transfer; no fertility studies
“Two administrations of a tarlatamab surrogate, mus757, that binds mouse CD3 and DLL3, to pregnant mice on gestational days (GD) 6 and GD 13 did not result in maternal toxicity or embryo-fetal development toxicity at doses ≤4500 µg/kg.”
✓ VerifiedFDA multi-discipline review, p. 50Source ↗
Safety pharmacology
Incorporated into monkey tox studies (ECG, respiratory rate, body temperature, neurologic exams)
“Electrocardiographic assessments, respiratory rate, body temperature measurements, and neurologic examinations were included on the toxicology studies in the cynomolgus monkey”
✓ VerifiedFDA multi-discipline review, p. 60Source ↗

Same question, other bispecifics

Bizengri

zenocutuzumab · HER2 x HER3
Not conducted (ICH S6(R1))

Blincyto

blinatumomab · CD19 x CD3
Not conducted (ICH S6(R1); protein of natural amino acids)

Columvi

glofitamab · CD20 x CD3
Not conducted (ICH S6(R1))

Elrexfio

elranatamab · BCMA x CD3
Not conducted (ICH S6(R1))

Epkinly

epcoritamab · CD20 x CD3
Not conducted (ICH S6(R1), ICH S9)

Hemlibra

emicizumab · FIXa x FX
Not conducted (ICH S6)

Kimmtrak

tebentafusp · CD3 x gp100 (TCR fusion)
Not conducted (fusion protein; ICH S6/S9)

Korjuny

catumaxomab · EpCAM x CD3
Not conducted (ICH S6(R1))

Lunsumio

mosunetuzumab · CD20 x CD3
Not conducted (ICH S6(R1))

Lynozyfic

linvoseltamab · BCMA x CD3
Not conducted (antibody not expected to interact with DNA)

Ordspono

odronextamab · CD20 x CD3
Not conducted (antibody not expected to interact with DNA)

Removab

catumaxomab · EpCAM x CD3
Not conducted (not submitted; biologic, no relevant model)

Rybrevant

amivantamab · EGFR x MET
Not conducted (not appropriate for antibodies)

Talvey

talquetamab · GPRC5D x CD3
Not conducted (ICH S6; biotechnology-derived product)

Tecvayli

teclistamab · BCMA x CD3
Not conducted (ICH S6(R1))

Vabysmo

faricimab · VEGF-A x Ang-2
Not conducted (ICH S6(R1))

Ziihera

zanidatamab · HER2 x HER2 (biparatopic)
Not conducted (ICH S6(R1), ICH S9)

Summary across all 18 bispecifics →